Use of bioluminescent imaging to investigate the role of nuclear factor-κB in experimental non-small cell lung cancer metastasis

Clinical and Experimental Metastasis

Volumn 25, Issue 1, 2008, Pages 43-51

  Stathopoulos, Georgios T ^a,b   Sherrill, Taylor P ^a   Han, Wei ^a   Sadikot, Ruxana T ^a   Polosukhin, Vasiliy V ^a   Fingleton, Barbara ^a   Yull, Fiona E ^a   Blackwell, Timothy S ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bioluminescence; Lewis lung cancer; Luciferase; Metastasis; Mouse model; NF B

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; TRANSCRIPTION FACTOR RELA;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; FEMALE; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PHOTON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION;

ANIMALS; CARCINOMA, LEWIS LUNG; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; I-KAPPA B KINASE; LUCIFERASES; LUMINESCENT AGENTS; LUNG NEOPLASMS; MICE; NEOPLASM METASTASIS; NF-KAPPA B; SYNAPTOTAGMIN I;

EID: 38949127039     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-007-9100-z     Document Type: Article

References (31)

1. Blackwell TS, Christman JW (1997) The role of nuclear factor-κB in cytokine gene regulation. Am J Respir Cell Mol Biol 17:3-9
2. Pahl HL (1999) Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18:6853-6866
3. Sadikot RT, Han W, Everhart MB et al (2003) Selective IκB Kinase expression in airway epithelium generates neutrophilic lung inflammation. J Immunol 170:1091-1098
4. Chen FE, Ghosh G (1999) Regulation of DNA binding by Rel/NF-kB transcription factors: structural views. Oncogene 18:6845-6852
5. Mercurio F, Zhu H, Murray BW et al (1997) IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science 278:860-866
6. Karin M (1999) How NF-κB is activated: the role of the IκB kinase (IKK) complex. Oncogene 18:6867-6874
7. Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106-130
8. Mukhopadhyay T, Roth JA, Maxwell SA (1995) Altered expression of the p50 subunit of the NF-κB transcription factor complex in non-small cell lung carcinoma. Oncogene 11:999-1003
9. Tang X, Liu D, Shishodia S et al (2006) Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 107:2637-2646
10. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860-867
11. Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710-1717
12. Stathopoulos GT, Zhu Z, Everhart MB et al (2006) Nuclear factor-κB activation affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol 34:142-150
13. Sadikot RT, Zeng H, Joo M et al (2006) Targeted immunomodulation of the NF-κB pathway in airway epithelium impacts host defense against Pseudomonas aeruginosa. J Immunol 176:4923-4930
14. phox deficiency impairs NF-κΒ activation and host defense in Pseudomonas pneumonia. J Immunol 172:1801-1808
15. Fidler IJ (1970) Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst 45:773-782
16. Jiang Y, Cui L, Yie TA et al (2001) Inhibition of anchorage-independent growth and lung metastasis of A549 lung carcinoma cells by IkBb. Oncogene 20:2254-2263
17. Kim D-M, Koo S-Y, Jeon K et al (2003) Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-α or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer Res 63:621-626
18. Andela VB, Schwarz EM, Puzas JE et al (2000) Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor-κB. Cancer Res 60:6557-6562
19. Ricca A, Biroccio A, Trisciuoglio D et al (2001) RelA over-expression reduces tumorigenicity and activates apoptosis in human cancer cells. Br J Cancer 85:1914-1921
20. Yamamoto Y, Gaynor RB (2001) Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 107:135-142
21. Dajee M, Lazarov M, Zhang JY et al (2003) NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421:639-643
22. Dong G, Chen Z, Kato T et al (1999) The host environment promotes the constitutive activation of nuclear factor-κB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res 59:3495-3504
23. Karin M, Cao Y, Greten FR et al (2002) NF-κB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2:301-310
24. Rollins BJ, Sunday ME (1991) Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol Cell Biol 11:3125-3131
25. Nokihara H, Yanagawa H, Nishioka Y et al (2000) Natural killer cell-dependent suppression of systemic spread of human lung adenocarcinoma cells by monocyte chemoattractant protein-1 gene transfection in severe combined immunodeficient mice. Cancer Res 60:7002-7007
26. Luo J-L, Maeda S, Hsu L-C et al (2004) Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNF-α to TRAIL-mediated tumor regression. Cancer Cell 6:297-305
27. Voorhees PM, Dees EC, O'Neil B et al (2003) The proteasome as a target for cancer therapy. Clin Cancer Res 9:6316-6325
28. Lenz HJ (2003) Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 29S1:41-48
29. Collett GP, Campbell FC (2006) Overexpression of p65/RelA potentiates curcumin-induced apoptosis in HCT116 human colon cancer cells. Carcinogenesis 27:1285-1291
30. Weissleder R (2002) Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer 2:1-8
31. Contag CH, Bachmann MH (2002) Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng 4:235-260